Compounds > venlafaxine
Page last updated: 2024-08-16

venlafaxine and duloxetine

venlafaxine has been researched along with duloxetine in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Burroughs, K; Cosmi, S; Deecher, DC; Ho, D; Johnston, G; Leiter, J; Mahaney, PE; Sabatucci, JP; Trybulski, E; Zhang, Y1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Dalvie, D; Loi, CM; Smith, DA1
Badescu, VO; de Frutos, O; de la Puente, ML; Ding, C; Dreyfus, N; Filla, SA; Fynboe, K; Gernert, DL; Heinz, BA; Hemrick-Luecke, SK; Iyengar, S; Johansson, AM; Johnson, KW; Johnson, MP; Joshi, E; López, P; Love, PL; Martin, LJ; Masquelin, T; McCoy, MJ; Mendiola, J; Morrow, D; Muhlhauser, M; Myers, JK; Pascual, G; Perun, TJ; Pfeifer, LA; Phebus, LA; Richards, SJ; Rincón, JA; Seest, EP; Shah, J; Shaojuan, J; Simmons, RM; Stephenson, GA; Thomas, CE; Thompson, LK; Tromiczak, EG; Walter, MW; Weber, WW; Zarrinmayeh, H1
Cheon, SH; Choi, K; Hahn, HG; Han, M; Song, C; Yun, J1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for venlafaxine and duloxetine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

6 other study(ies) available for venlafaxine and duloxetine

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2010, May-01, Volume: 20, Issue:9

    Topics: Animals; Crystallography, X-Ray; Ethylamines; Humans; Molecular Conformation; Neurotransmitter Uptake Inhibitors; Norepinephrine; Piperazines; Rats; Structure-Activity Relationship; Thiophenes

2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Which metabolites circulate?
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5

    Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations

2013
Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.
    ACS medicinal chemistry letters, 2013, Jun-13, Volume: 4, Issue:6

    Topics:

2013
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2014, Aug-01, Volume: 24, Issue:15

    Topics: Azetidines; Biological Transport; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Neurotransmitter Uptake Inhibitors; Phenyl Ethers; Plasma Membrane Neurotransmitter Transport Proteins; Serotonin; Structure-Activity Relationship

2014